Author Archives: Ben Comer

Emerging Pharma Leaders: Jamey Millar, GSK

Storytelling, since time immemorial, has served an important role in conveying information, expectations, and obligations. Stories can function as orientation guides, uniting readers or listeners around a common set of assumptions. The best stories also contain an element of surprise, a reminder of the unexpected possibilities, and chance occurrences that bind our lives together. After […]
Posted in leadership | Tagged , , | Leave a comment

Abrams Talks Social Media at DIA

“It doesn’t turn me on to send a warning letter.” –Tom Abrams, during a Q&A at DIA.  Instead of repeating his yearly Drug Information Association (DIA) conference claim that social media guidance remains among the FDA’s Office of Prescription Drug Promotion’s (OPDP) “highest priorities,” to be published in due course, Tom Abrams, director of OPDP, […]
Posted in Advertising, E-Media, FDA, Legal, Marketing, Meetings, Patient Communication, Regulatory, social media, Strategy, Technology | Tagged , , , , , | Leave a comment

Pharm Exec's Brands of Yesteryear: Where Are They Now?

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others. The US drug pricing wars may be coming, but these products already made their mint. We checked back in with them to see how things are going, and to look […]
Posted in Pharm Exec Magazine, R&D, Strategy | Tagged , , , , , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

Are Drug Ads in Print Journals Still Effective?

If the American public could shed girth as quickly as many medical journals have in recent years, we’d all be a lot healthier. Collectively, medical journals dropped over 4,200 pages in 2013, as reported by MM&M last month, a direct result of fewer ad buys in the category. Professional marketers have steadily shifted resources into […]
Posted in Advertising, Agency Insight, Marketing, Sales, Technology | Tagged , , , | 1 Comment
  • Categories

  • Meta